205 related articles for article (PubMed ID: 12911851)
1. Toxicity of antilipidemic agents: facts and fictions.
Xydakis AM; Jones PH
Curr Atheroscler Rep; 2003 Sep; 5(5):403-10. PubMed ID: 12911851
[No Abstract] [Full Text] [Related]
2. Clinical inquiries. Should liver enzymes be checked in a patient taking niacin?
Rizakallah GS; Mertens MK; Brown ML; Sanner L
J Fam Pract; 2005 Mar; 54(3):265-8. PubMed ID: 15755381
[No Abstract] [Full Text] [Related]
3. Statin-fibrate combination therapy.
Shek A; Ferrill MJ
Ann Pharmacother; 2001; 35(7-8):908-17. PubMed ID: 11485144
[TBL] [Abstract][Full Text] [Related]
4. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect?
Langford NJ; Kendall MJ
J Clin Pharm Ther; 2001 Dec; 26(6):391-5. PubMed ID: 11722675
[No Abstract] [Full Text] [Related]
5. Risk for myopathy with statin therapy in high-risk patients.
Ballantyne CM; Corsini A; Davidson MH; Holdaas H; Jacobson TA; Leitersdorf E; März W; Reckless JP; Stein EA
Arch Intern Med; 2003 Mar; 163(5):553-64. PubMed ID: 12622602
[TBL] [Abstract][Full Text] [Related]
6. [Mechanisms of hepatotoxicity].
Bertolami MC
Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():25-7. PubMed ID: 16400394
[TBL] [Abstract][Full Text] [Related]
7. Niacin's effect on cardiovascular risk: have we finally learned our lesson?
Nicholls SJ
Cleve Clin J Med; 2014 May; 81(5):275-7. PubMed ID: 24789584
[No Abstract] [Full Text] [Related]
8. Rhabdomyolysis due to combination therapy with cerivastatin and gemfibrozil.
Alexandridis G; Pappas GA; Elisaf MS
Am J Med; 2000 Aug; 109(3):261-2. PubMed ID: 11023440
[No Abstract] [Full Text] [Related]
9. Needed: pragmatic clinical trials for statin-intolerant patients.
Maningat P; Breslow JL
N Engl J Med; 2011 Dec; 365(24):2250-1. PubMed ID: 22085320
[No Abstract] [Full Text] [Related]
10. Combining niacin with statins: does it help heart health?
Johns Hopkins Med Lett Health After 50; 2011 Dec; 23(10):1-2. PubMed ID: 22216465
[No Abstract] [Full Text] [Related]
11. Statin intolerance: now a solved problem.
Sikka P; Kapoor S; Bindra VK; Sharma M; Vishwakarma P; Saxena KK
J Postgrad Med; 2011; 57(4):321-8. PubMed ID: 22120862
[TBL] [Abstract][Full Text] [Related]
12. [HMG-CoA reductase inhibitors (statin)].
Yamamura T; Ishigami M
Nihon Rinsho; 2007 Jul; 65 Suppl 7():458-64. PubMed ID: 17824071
[No Abstract] [Full Text] [Related]
13. Pleiotropic effects of niacin: Current possibilities for its clinical use.
Zeman M; Vecka M; Perlík F; Staňková B; Hromádka R; Tvrzická E; Širc J; Hrib J; Žák A
Acta Pharm; 2016 Dec; 66(4):449-469. PubMed ID: 27749252
[TBL] [Abstract][Full Text] [Related]
14. Drugs for lipids.
Treat Guidel Med Lett; 2014 Jan; 12(137):1-6; quiz 7-8. PubMed ID: 24419209
[No Abstract] [Full Text] [Related]
15. [Nicotinic acid and the derivative].
Ogaki S; Matsushima T
Nihon Rinsho; 2001 Mar; 59 Suppl 3():637-41. PubMed ID: 11347146
[No Abstract] [Full Text] [Related]
16. Combination drug therapy for combined hyperlipidemia.
Guyton JR
Curr Cardiol Rep; 1999 Sep; 1(3):244-50. PubMed ID: 10980849
[TBL] [Abstract][Full Text] [Related]
17. New analysis supports expanded use of statins in women.
Harv Womens Health Watch; 2010 Apr; 17(8):6. PubMed ID: 20506603
[No Abstract] [Full Text] [Related]
18. Lipid-lowering agents that cause drug-induced hepatotoxicity.
Bhardwaj SS; Chalasani N
Clin Liver Dis; 2007 Aug; 11(3):597-613, vii. PubMed ID: 17723922
[TBL] [Abstract][Full Text] [Related]
19. Use of lipid-lowering agents (statins) during pregnancy.
Hosokawa A; Bar-Oz B; Ito S
Can Fam Physician; 2003 Jun; 49():747-9. PubMed ID: 12836860
[TBL] [Abstract][Full Text] [Related]
20. Comparative effects of lipid-lowering therapies.
Davidson MH; Toth PP
Prog Cardiovasc Dis; 2004; 47(2):73-104. PubMed ID: 15586350
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
